COVID-19 Vaccine
61
4
6
34
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
3.3%
2 terminated out of 61 trials
94.4%
+7.9% vs benchmark
11%
7 trials in Phase 3/4
6%
2 of 34 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 34 completed trials
Clinical Trials (61)
Pancoronavirus Vaccine Study in Healthy Adults
Covid-19 Vaccine Response in Elderly Subjects
SCIVAX: Biomarkers of Immune Dysfunction and Vaccine Responsiveness in Chronic SCI
Iron and COVID-19 Vaccine Response
Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine
Phase IIB Study of Recombinant Novel Coronavirus Vaccine
Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1c
Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases
Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers
A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC (Phase 1)
Researchers At UC San Diego Are Learning About the Benefits of Human Milk and How It Influences Infant and Child Health
COVID-19 Vaccination Hesitancy in Adults With Sickle Cell Disease
Immunogenicity Induced by COVID-19 Vaccines in Mexican Population
A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose.
Enabling Family Physicians to Reduce Vaccine Hesitancy and Increase Covid-19 Vaccine Uptake
A Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV1901 in Adults
Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong
Covid-19 Vaccine Response in Heart Transplant Recipients
Safety and Immunogenicity of Recombinant COVID-19 Trivalent Protein Vaccine (CHO Cell)LYB002V14 in Booster Vaccination
ARVAC - A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine